Pricing for Oncology Biosimilars—Reply | ClinicLens
In Reply I thank Drs Jensen and Tichy for the opportunity to respond to the comments on our article on hospital adoption and pricing for oncology biosimilars. Their comments are factually correct and add insight into the complex process of drug payment and strengthen the core mes
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.